Importance of tumor necrosis factor-alpha cleavage process in post-transplantation lung injury in rats.
Tumor necrosis factor-alpha (TNF-alpha) has two forms with apparently different biological activities: a membrane-associated form and a soluble form. TNF-alpha-converting enzyme (TACE) mediates a cleavage of membrane-associated TNF-alpha to induce its bioactive soluble form. We hypothesized that inhibition of TACE might prevent TNF-alpha-induced tissue injury while preserving the benefits of TNF-alpha. In this study, we evaluated the role of TACE in acute inflammation using an inhibitor of the enzyme in a rat model of lung transplantation. Inbred Lewis rats underwent left lung isotransplantation, and the donor lungs were kept in Euro-Collins solution with or without the inhibitor. After 6 hours of ischemia, the left lung was transplanted into the recipient rat and reperfused for 4 hours. Inhibition of TACE significantly attenuated endothelial and alveolar septal damage, as assessed by radiolabeled albumin leakage after transplantation. The inhibition also attenuated neutrophil accumulation in the alveolar space and other histopathologic findings, including intercellular adhesion molecule-1 expression. In addition, significantly lower levels of monocyte chemotactic protein-1, cytokine-induced neutrophil chemoattractant-1, high mobility group box-1, and soluble epithelial cadherin and decreased neutrophil elastase activity were observed in bronchoalveolar lavage fluid from the rats treated with the inhibitor. We conclude that TACE mediates a critical step in the development of post-transplantation lung injury.
Goto
Taichiro
T
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Ishizaka
Akitoshi
A
Kobayashi
Fujio
F
Kohno
Mitsutomo
M
Sawafuji
Makoto
M
Tasaka
Sadatomo
S
Ikeda
Eiji
E
Okada
Yasunori
Y
Maruyama
Ikuro
I
Kobayashi
Koichi
K
D051722:ADAM Proteins; D000072198:ADAM17 Protein; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D015820:Cadherins / Q000276:immunology; D018925:Chemokines / Q000276:immunology; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D024243:HMGB1 Protein / Q000276:immunology; D008171:Lung Diseases / Q000276:immunology* / Q000517:prevention & control; D016040:Lung Transplantation / Q000009:adverse effects*; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D023421:Models, Animal; D051381:Rats; D011917:Rats, Inbred Lew; D020545:Respiratory Mucosa / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000378:metabolism*
D015820:Cadherins; D018925:Chemokines; D004791:Enzyme Inhibitors; D024243:HMGB1 Protein; D014409:Tumor Necrosis Factor-alpha; D051722:ADAM Proteins; D008666:Metalloendopeptidases; D000072198:ADAM17 Protein; C000606464:Adam17 protein, rat